Skip to main content
Caplight Logo









Javelin Biotech

Javelin Biotech

Private
Woburn, MassachusettsHealthcare & Life Scienceshttps://javelinbiotech.com/

Last Round

Grant

Jun 16, 2026

Total Funding Raised

$4.73M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Javelin Biotech is a biotechnology company that develops predictive drug discovery platforms merging human tissue chips with computational biology and machine learning to improve preclinical R&D productivity.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Hardware + Subscription, Data as a Service

AI Layer

Application

Keywords

organ-on-a-chipmicrophysiological systemsMPSpreclinical drug discoverydigital twinpharmacokineticsPKADMEin vitro testinganimal-free testingdrug development platformperfusion controllertissue chippredictive toxicologybiotech hardware

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Javelin Biotech Comparables

Compare Javelin Biotech with similar companies based on industry and business-model similarity.

Javelin Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Xellar Biosystems
85%
BiomimX
82%
Vivodyne
82%

Javelin Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 16, 2026
GrantAug 30, 2023
GrantAug 18, 2022
GrantSep 21, 2021
SeedSep 3, 2019

Key People

Founding team and executive leadership

Murat Cirit

CEO & Co-Founder

Founding Team

Javelin Biotech Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors increased 49% MoM, from 757 to 1.1K.

  • May 15, 2026

    Monthly visitors grew 208% MoM, reaching 1.9K.

Javelin Biotech Filings

Explore SEC and related filing metadata, where available.

Javelin Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Javelin Biotech's valuation, stock price, and market status.

Is Javelin Biotech a public or private company?

Javelin Biotech is a private company.

What is the current stock price of Javelin Biotech?

Javelin Biotech is a private company with no public stock price. No recent secondary market data is available.

How much is Javelin Biotech worth (valuation)?

Valuation information for Javelin Biotech is not publicly available.

Can I buy Javelin Biotech stock?

Javelin Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Javelin Biotech's last funding round?

Javelin Biotech's most recent funding round was Grant on June 16, 2026.

Who are the main investors in Javelin Biotech?

Key investors in Javelin Biotech include InnoSpark Ventures.

Will Javelin Biotech IPO soon?

No public IPO plans have been announced for Javelin Biotech.

How can I track Javelin Biotech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Javelin Biotech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersWoburn, Massachusetts
Employee Range7
Year Founded2019
Last FundingJun 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?